Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/ Refractory Acute Myeloid Leukemia

Main Inclusion Criteria:

1. Patients with relapsed or primary refractory AML (as defined in WHO criteria) with >5% bone marrow blasts
2. Patients with CD123+ blast cells (verified by flow cytometry)
3. Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of ≤1
4. Adequate organ function, including bone marrow, renal, hepatic, pulmonary, and cardiac function based on the last assessment performed within screening period
5. (Dose-escalation) Identified donor and transplant strategy prior to lymphodepletion (LD)
6. Other criteria may apply

Main Exclusion Criteria:

1. Patients with APL or CNS Leukemia
2. Previous investigation gene or cell therapy (including CAR)
3. ≥ 2 prior allogeneic SCTs
4. Prior treatment with rituximab or other anti-CD20 therapy within 3 months
5. Any known active or uncontrolled infection
6. Other criteria may apply